当前亚健康普遍化、需求个性化，传统养生难以适配。煦堂生物以"科技+中医"为核心，推出桴德五衡茶，依托中医九大体质理论，融合AI辨识、大数据、 纳米萃取技术，打造"辨体饮茶、精准养生"模式，将"治未病"转化为日常可及、便捷高效的健康方案，实现体质调理与生活场景深度融合。 经济观察网2026年2月8日，煦堂生物集团在北京举办以"推动'中医现代化'，引领健康生活新范式"为主题的桴德五衡茶品牌盛典。国医大师、院士、行业专 家及产业、投资、媒体代表齐聚，共探科技赋能中医、精准养生落地新路径，助力健康中国与全民百岁人生建设。 会上，叶祖光、孙德海、方京徽等专家分别从科研、产业、临床角度，肯定"传承精华、守正创新"路径，认为项目实现从"辨证"到"辨体"的现代化跨越，为 中医药消费转化树立范本。创始人周宁院士表示，产品以循证与科技构建可感知、可持续的日常健康系统，让中医智慧走进大众生活。 活动同步发布《中西医联手，养成不爱生病体质》新书，夯实学术与科普支撑；举行品牌启动仪式，发布渠道合作政策，规划线下体验店"桐调坊"，推 进"百城千店"布局。 与会专家认为，桴德五衡茶以科技活化中医经典，推动健康管理从被动治疗转向主动养护，为 ...

来源：环球网 2026年2月8日，北京讯 —— 在"百岁人生"时代浪潮与科技高速发展的双重背景下，中医现代化正成为 健康中国战略的重要引擎。今日，以"推动'中医现代化'，引领健康生活新范式"为主题的桴德五衡茶品 牌盛典在北京隆重举行。本次盛典由煦堂生物集团主办，聚焦于如何以人工智能、大数据、纳米萃取等 前沿科技赋能中医高质量发展，通过科学辨体与中医千年智慧相结合，为大众提供精准、便捷的健康养 生解决方案，助力全民步入高质量百岁人生。 盛典汇聚了中医药学界、产业界、投资界及媒体界数百位嘉宾，包括行业协会领导、英国皇家工艺院终 身院士、国医大师、临床专家及健康领域领军人物，现场高朋满座，共同见证了一场关于中医未来与健 康产业变革的思想盛宴。 合的道路，认为这是让中医药在当代焕发新生、走向国际的重要路径。他特别指出，桴德五衡茶基于严 谨体质辨识的产品研发逻辑，体现了中医"因人制宜"的核心思想在现代社会的创新应用。 时代呼唤：科技赋能中医，开启精准健康管理百岁人生新时代 当前，我国居民健康意识全面觉醒，亚健康状态普遍化、健康需求个性化与信息碎片化之间的矛盾日益 突出。传统"一刀切"的养生方式已难以满足当代人对精准、有 ...

Core Insights - The company, Shenzhen Beiliang Technology Co., Ltd. (倍轻松), reported a revenue of 385 million yuan for the first half of 2025, continuing to deepen its core strategy of "technology empowering health" [1] - The company invested 27.02 million yuan in R&D, accounting for 7.02% of its revenue, and has a total of 113 R&D personnel [1] - The company launched multiple new products, including the Ginger Xiaozhu A3 and various massage devices, while also upgrading key products [1] - In the field of scalp health, the company integrated low-level laser therapy with smart massage combs, establishing a foundation for entering the high-end health market in Europe and the U.S. [1] Product Development - The company has developed a "hardware + content + service" solution for sleep health, creating a closed-loop management system [2] - The company achieved breakthroughs in modernizing traditional Chinese medicine, including moxibustion carbon technology and meridian sound therapy systems [3] - The company is embracing AI development, with a focus on integrating AI into product R&D, including an upgraded traditional Chinese medicine constitution identification model [3] Future Projects - The company announced the use of surplus funds from its "Information Technology Upgrade Project" for building a sensor matrix focused on immersive interaction [3] - The project aims to develop multi-modal sensors for precise environmental perception, user behavior prediction, and personalized health services [3]

Core Viewpoint - WenZhiTCM Inc. is making a second attempt to go public on the Hong Kong Stock Exchange, leveraging its "Traditional Chinese Medicine + AI" model to maintain a leading market share in the industry for two consecutive years [1][2]. Company Overview - Founded in 2018, WenZhiTCM is led by founder Cui Xiangrui, who has a diverse background in life sciences and business management, along with experience in medical investments [1]. - The company operates three main business segments: online internet hospitals, offline TCM clinics, and TCM smart products, which include various health products and subscription services [1]. Financial Performance - The updated prospectus reveals significant revenue growth, with earnings reported as follows: 62.169 million RMB in 2022, approximately 189 million RMB in 2023, approximately 236 million RMB in 2024, 89.848 million RMB for the first five months of 2025, and approximately 100 million RMB [2][6]. AI Integration - The proprietary AI-assisted diagnostic system, "Traditional Chinese Medicine Brain," has been developed using over one million clinical cases, creating a knowledge graph covering over 3,000 diseases [4]. - This system has been implemented in over 2,000 medical institutions nationwide, significantly enhancing diagnostic efficiency and accuracy [4]. Market Potential - The AI-assisted TCM market is projected to grow rapidly, with AI penetration expected to rise from 1.4% in 2024 to 5.4% in 2029, and the market size anticipated to increase from 16 billion RMB in 2024 to 100.1 billion RMB by 2029, reflecting a compound annual growth rate of 44.3% [5]. Business Model - WenZhiTCM has established a comprehensive online and offline ecosystem, with online medical services accounting for 90% of its revenue, supported by 12 self-operated clinics and 4 regional herbal medicine centers [7]. - The company also offers TCM lifestyle products through its e-commerce platform, which has shown high growth rates and potential for cross-selling [7]. B2B Opportunities - The "Traditional Chinese Medicine Brain" subscription service is expanding its client base among TCM medical institutions, contributing to new profit growth [8]. - The company provides professional training through its online education platform, enhancing user engagement and creating a complete service chain [8]. Industry Support - The National Administration of Traditional Chinese Medicine has outlined plans to develop intelligent diagnostic systems, emphasizing the integration of modern technology with TCM [4]. - The market for digital TCM is expected to grow at a compound annual growth rate of 51.4%, reaching 86.9 billion RMB by 2028, positioning WenZhiTCM as a leading player in this transformation [8].